TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14520775

Group type: EXPERIMENTAL
Intervention: 19% sodium percarbonate film (Crest Night Effects) applied overnight
Number of subjects: 38

Group type: COMPARATOR
Intervention: 18% carbamide peroxide gel (Colgate Simply White) applied twice daily
Number of subjects: 38
Study: 10919929

Group type: COMPARATOR
Intervention: O(fat)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: O(cho)
Number of subjects: 13
Study: 9365358

Group type: EXPERIMENTAL
Intervention: Subacromial local anesthetic injection
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (healthy controls)
Number of subjects: 19
Study: 1586077

Group type: EXPERIMENTAL
Intervention: EWLW management group (n=52)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Wedge pressure (WP) management group (n=49)
Number of subjects: 101
Study: 3894125

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional insulin therapy (CIT)
Number of subjects: 0
Study: 31300260

Group type: EXPERIMENTAL
Intervention: active intermittent theta burst stimulation (iTBS)
Number of subjects: 28

Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: active iTBS
Number of subjects: 28
Study: 29032294

Group type: EXPERIMENTAL
Intervention: High frequency Cg25 stimulation (130 Hz)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Low frequency Cg25 stimulation (20 Hz)
Number of subjects: 9
Study: 27871575

Group type: EXPERIMENTAL
Intervention: Alfentanil 55 μg/kg
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Alfentanil doses (0, 10, 20, 30, 40, 50, and 60 μg/kg)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Alfentanil (various doses)
Number of subjects: 84
Study: 24172057

Group type: EXPERIMENTAL
Intervention: Earplugs and eye masks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 46
Study: 22775448

Group type: COMPARATOR
Intervention: Weekly Swedish massage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Twice-weekly Swedish massage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Light touch control
Number of subjects: 0
Study: 21172026

Group type: EXPERIMENTAL
Intervention: Contingency management (CM) intervention for 12 weeks
Number of subjects: 127

Group type: COMPARATOR
Intervention: Referral to community resources (Control)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Contingency management (CM) intervention
Number of subjects: 127
Study: 18201457

Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (TA) 100 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (TA) 1 g
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combined results from TA groups (100 mg and 1 g)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Topical epsilon‐aminocaproic acid (EACA)
Number of subjects: 30
Study: 15744632

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (TD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11999539

Group type: EXPERIMENTAL
Intervention: High-glycemic index diet (75 GI units)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Low-glycemic index diet (43 GI units)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Both high- and low-glycemic index diets
Number of subjects: 45
Study: 9816716

Group type: EXPERIMENTAL
Intervention: Mivacurium (non-priming group, n = 20) - 0.25 mg/kg as a single intubating dose
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mivacurium (priming group, n = 20) - 0.225 mg/kg preceded by 0.025 mg/kg 3 min earlier
Number of subjects: 60

Group type: COMPARATOR
Intervention: Succinylcholine (control group, n = 20) - 1 mg/kg as an intubating bolus
Number of subjects: 60
Study: 7814828

Group type: EXPERIMENTAL
Intervention: Eltoprazine
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 2700113

Group type: EXPERIMENTAL
Intervention: 5 mg/day mepindolol (Group A)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 200 mg/day metoprolol duriles (Group B)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (Group C)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both beta-blockers (mepindolol and metoprolol)
Number of subjects: 19
Study: 29460812

Group type: EXPERIMENTAL
Intervention: Black tea (∼400 mg flavonoids, equivalent to 2-3 cups of tea)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (taste- and color-matched)
Number of subjects: 20
Study: 27241836

Group type: EXPERIMENTAL
Intervention: Acute aspirin supplementation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Chronic aspirin supplementation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Aspirin supplementation
Number of subjects: 24
Study: 24771721

Group type: COMPARATOR
Intervention: Control DDDR
Number of subjects: 1166

Group type: EXPERIMENTAL
Intervention: DDDRP + MVP
Number of subjects: 1166

Group type: EXPERIMENTAL
Intervention: MVP
Number of subjects: 1166
Study: 24367492

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day)
Number of subjects: 672

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 672
Study: 21405957

Group type: EXPERIMENTAL
Intervention: Allopurinol (150 mg daily for 8 weeks) with ACE-I (perindopril)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Allopurinol (150 mg daily for 8 weeks) with thiazide (hydrochlorothiazide)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 66
Study: 18626522

Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg premedication
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 16571846

Group type: EXPERIMENTAL
Intervention: Omitting a meal
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Adding a meal
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (usual four-meal pattern)
Number of subjects: 24
Study: 14610410

Group type: EXPERIMENTAL
Intervention: 150 mg bicalutamide
Number of subjects: 0
Study: 11212479

Group type: EXPERIMENTAL
Intervention: Fusidic acid cream applied in nostrils, 20 mg/gm, twice a day for four weeks
Number of subjects: 30
Study: 9104518

Group type: EXPERIMENTAL
Intervention: Group 1A (portal injections with lidocaine, intraarticular lidocaine, placebo femoral nerve block)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group FNB (femoral 3-in-1 nerve block with chloroprocaine, placebo portal injections, placebo intraarticular saline)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group FNB + IA (femoral 3-in-1 nerve block, intraarticular lidocaine, placebo portal injections)
Number of subjects: 60

Group type: COMPARATOR
Intervention: All groups (combined)
Number of subjects: 60
Study: 1487923

Group type: EXPERIMENTAL
Intervention: Low-intensity Nautilus circuit training program (14 exercises, 30% of maximum) for six weeks, three times per week.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no training).
Number of subjects: 26
Study: 3549871

Group type: EXPERIMENTAL
Intervention: CNS stimulants (methylphenidate)
Number of subjects: 0
Study: 31962052

Group type: EXPERIMENTAL
Intervention: Virtual Reality Relaxation (VRR)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 255
Study: 30002346

Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy (WBC) treatment after exercise (-140 °C, 3 min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (CON) trial (rest period after exercise)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy (WBC) treatment after exercise
Number of subjects: 12
Study: 26400901

Group type: EXPERIMENTAL
Intervention: Joint mobilization combined with stretching exercises (JM&Str)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Steroid injection (SI)
Number of subjects: 43
Study: 24881898

Group type: EXPERIMENTAL
Intervention: 20 minutes of questionnaires (participate in research)
Number of subjects: 128

Group type: COMPARATOR
Intervention: No participation in research (control)
Number of subjects: 128
Study: 22265921

Group type: EXPERIMENTAL
Intervention: NT‐proBNP >1800 pg/mL
Number of subjects: 1086

Group type: EXPERIMENTAL
Intervention: NT‐proBNP <150 pg/mL
Number of subjects: 1086

Group type: EXPERIMENTAL
Intervention: NT‐proBNP (general correlation)
Number of subjects: 1086
Study: 19720489

Group type: EXPERIMENTAL
Intervention: Single-dose gadobutrol (0.1 mmol/kg b.w.)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Double-dose gadobutrol
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Single-dose gadobenate-dimeglumine
Number of subjects: 16
Study: 18375324

Group type: EXPERIMENTAL
Intervention: Remifentanil (0.3 microg/kg/min, n = 45)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (n = 45)
Number of subjects: 90
Study: 16568409

Group type: EXPERIMENTAL
Intervention: Weight training (twice-weekly)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 86
Study: 12666710

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine mouthrinse (15 ml, 30 seconds)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0.2% chlorhexidine mouthrinse (10 ml, 60 seconds)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Questionnaire results for taste perception, duration of taste, alteration in taste, perceived plaque reduction
Number of subjects: 80
Study: 10607709

Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated HIV-1 infection
Number of subjects: 0
Study: 9194621

Group type: EXPERIMENTAL
Intervention: Maternal intravenous magnesium sulfate therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (mothers not receiving magnesium sulfate)
Number of subjects: 0
Study: 1535083

Group type: EXPERIMENTAL
Intervention: BAY u 3405 (20 mg orally 1 hour before challenges)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3032562

Group type: EXPERIMENTAL
Intervention: enalapril 10 mg orally
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: enalapril 5 mg intravenously
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: enalaprilat 5 mg intravenously
Number of subjects: 12

Group type: COMPARATOR
Intervention: enalapril (oral and intravenous) and enalaprilat (intravenous)
Number of subjects: 12
Study: 31837719

Group type: EXPERIMENTAL
Intervention: Close relationships with students
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conflictual relationships with students
Number of subjects: 0
Study: 28660640

Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Ledipasvir (SOF/LDV) for 12 weeks
Number of subjects: 196

Group type: COMPARATOR
Intervention: Pegylated‐IFN/Ribavirin (RBV)
Number of subjects: 196
Study: 26277355

Group type: EXPERIMENTAL
Intervention: Warmed IV fluids
Number of subjects: 126

Group type: COMPARATOR
Intervention: Room temperature IV fluids
Number of subjects: 126
Study: 23213082

Group type: EXPERIMENTAL
Intervention: Restorative occupational therapy intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study: 21577124

Group type: EXPERIMENTAL
Intervention: iomeprol-400 (Iomeron, Bracco Imaging SpA, Milan, Italy)
Number of subjects: 96

Group type: COMPARATOR
Intervention: iodixanol-320 (Visipaque, GE Healthcare, Chalfont St. Giles, United Kingdom)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: iomeprol-400
Number of subjects: 96

Group type: COMPARATOR
Intervention: iodixanol-320
Number of subjects: 96
Study: 19300369

Group type: EXPERIMENTAL
Intervention: EMD+CAF
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CTG+CAF
Number of subjects: 12
Study: 16814225

Group type: EXPERIMENTAL
Intervention: Maternal knee-chest posture
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 25
Study: 15646221

Group type: EXPERIMENTAL
Intervention: Group 1: filled with two horizontal increments
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group 2: filled with two horizontal increments, first up to half cavity height and light cured using a transparent plastic cone (Cerana), second filling remainder of cavity
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group 3: filled in the same way as Group 2, except first increment only filled one‐third of cavity height
Number of subjects: 30
Study: 11158452

Group type: EXPERIMENTAL
Intervention: Early dexamethasone treatment
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Early dexamethasone
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 570

Group type: COMPARATOR
Intervention: Inhaled budesonide
Number of subjects: 570

Group type: COMPARATOR
Intervention: Delayed selective treatment
Number of subjects: 570
Study: 9242847

Group type: EXPERIMENTAL
Intervention: Outreach treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hospital treatment
Number of subjects: 50
Study: 8112550

Group type: EXPERIMENTAL
Intervention: Intradermal vaccination
Number of subjects: 119

Group type: COMPARATOR
Intervention: Intramuscular vaccination
Number of subjects: 119
Study: 3298406

Group type: EXPERIMENTAL
Intervention: Lymphoblastoid interferon (thrice weekly for 6 months after a 5-day induction phase)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Lymphoblastoid interferon
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (no therapy)
Number of subjects: 32
Study: 30348206

Group type: EXPERIMENTAL
Intervention: Amitriptyline supplemented with pregabalin
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Pregabalin supplemented with amitriptyline
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Duloxetine supplemented with pregabalin
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 392
Study: 26763030

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best medical care alone
Number of subjects: 0
Study: 24219399

Group type: EXPERIMENTAL
Intervention: Core disgust stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Painful injuries
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral scenes
Number of subjects: 0
Study: 23213979

Group type: EXPERIMENTAL
Intervention: Acupuncture at Neiguan (PC 6) and Zusanli (ST 36)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Dolantin
Number of subjects: 240

Group type: COMPARATOR
Intervention: Scopolamine
Number of subjects: 240
Study: 20556258

Group type: EXPERIMENTAL
Intervention: Platform-switched implants (n = 75)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nonplatform-switched implants (n = 14)
Number of subjects: 36
Study: 18609248

Group type: EXPERIMENTAL
Intervention: Activity-based assessment (BIA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard assessment (SA)
Number of subjects: 0
Study: 16150764

Group type: EXPERIMENTAL
Intervention: Social behaviour and network therapy
Number of subjects: 742

Group type: COMPARATOR
Intervention: Motivational enhancement therapy
Number of subjects: 742
Study: 12020739

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (360 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ginseng (400 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ginkgo/ginseng combination (960 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10071829

Group type: EXPERIMENTAL
Intervention: Narpan (generic naltrexone)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Trexan (innovator product)
Number of subjects: 12
Study: 7560624

Group type: EXPERIMENTAL
Intervention: Intracoronary urokinase
Number of subjects: 469

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 469
Study: 2076318

Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Amoxyciclin + clavulanic
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Povidone‐iodine
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 6101739

Group type: EXPERIMENTAL
Intervention: Epidural analgesia (T4 to S5)
Number of subjects: 12

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 12
Study: 30624753

Group type: EXPERIMENTAL
Intervention: Micronutrient powder (MNP) with 0 mg Zn/sachet
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Micronutrient powder (MNP) with 5 mg Zn/sachet
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Micronutrient powder (MNP) with 10 mg Zn/sachet
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Micronutrient powder (MNP) with 15 mg Zn/sachet
Number of subjects: 74

Group type: COMPARATOR
Intervention: Comparison with published data on child zinc absorption
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Relation of TAZ to serum α‐1 acid glycoprotein and fecal Entamoeba histolytica
Number of subjects: 74
Study: 29343230

Group type: EXPERIMENTAL
Intervention: Real-time functional magnetic resonance imaging neurofeedback (3 sessions within 2 weeks)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Downregulate the ventral striatum
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Upregulate the right inferior frontal gyrus
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Negatively modulate the connectivity between ventral striatum and right inferior frontal gyrus
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Upregulate the auditory cortex
Number of subjects: 100

Group type: COMPARATOR
Intervention: Downregulate the auditory cortex (control region)
Number of subjects: 100
Study: 26728311

Group type: EXPERIMENTAL
Intervention: Anesthetic circuit
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bag-valve-mask (BVM)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: BVM with nasal cannula (NC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: BVM with positive end-expiratory pressure valve (PEEP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: BVM + NC + PEEP
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nonrebreather mask (NRM)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: NRM + NC
Number of subjects: 30
Study: 24503952

Group type: EXPERIMENTAL
Intervention: Etravirine (ETR) 400 mg/day
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (continued protease inhibitor regimen)
Number of subjects: 43
Study: 22824079

Group type: EXPERIMENTAL
Intervention: S-1 40 mg/m2 bid for 21 days plus cisplatin 60 mg/m2 (day 8) every 5-week cycle
Number of subjects: 100

Group type: COMPARATOR
Intervention: Capecitabine 1000 mg/m2 bid for 14 days plus cisplatin 80 mg/m2 (day 1) every 3-week cycle
Number of subjects: 100
Study: 19157559

Group type: EXPERIMENTAL
Intervention: 1% brinzolamide 3 times per day
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 0.5% timolol gel forming solution once every morning
Number of subjects: 26
Study: 17998079

Group type: EXPERIMENTAL
Intervention: Mixed-mode survey design (phone administration followed by mail follow-up for nonresponders)
Number of subjects: 1900

Group type: EXPERIMENTAL
Intervention: Poststratification weighting adjustments (targeted)
Number of subjects: 1900
Study: 14729431

Group type: EXPERIMENTAL
Intervention: Seropositive for IgG antibodies at baseline
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Seropositive for IgA antibodies at baseline
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Increasing anti-Chlamydia pneumoniae antibody titers
Number of subjects: 272

Group type: COMPARATOR
Intervention: Control group (age- and gender-matched patients without coronary events)
Number of subjects: 272
Study: 12078851

Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide 5%/clindamycin phosphate 1% gel
Number of subjects: 60

Group type: COMPARATOR
Intervention: Clindamycin phosphate 1% solution
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 60
Study: 10825836

Group type: EXPERIMENTAL
Intervention: Glutaraldehyde with zinc oxide eugenol dressing
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Glutaraldehyde with calcium hydroxide dressing
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Overall success rate for glutaraldehyde
Number of subjects: 61
Study: 8678260

Group type: EXPERIMENTAL
Intervention: Reinforced laryngeal mask airway
Number of subjects: 66

Group type: COMPARATOR
Intervention: Tracheal intubation followed by Guedel airway
Number of subjects: 66
Study: 2110388

Group type: COMPARATOR
Intervention: 21% standard amino acids (STD)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 46% branched-chain amino acids (HBC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (STD and HBC)
Number of subjects: 20
Study: 368965

Group type: EXPERIMENTAL
Intervention: 40% idoxuridine (IDU) dissolved in dimethyl sulphoxide (DMSO)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Polyethylene glycol ointment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ointment with 60% DMSO
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ointment with 5% IDU and 60% DMSO
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ointment with 40% IDU and 60% DMSO
Number of subjects: 100
Study: 31204031

Group type: EXPERIMENTAL
Intervention: McKenzie method
Number of subjects: 70

Group type: COMPARATOR
Intervention: Motor control exercises
Number of subjects: 70
Study: 28710459

Group type: EXPERIMENTAL
Intervention: Genioplasty templates (experimental group)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Traditional intraoperative measurements (control group)
Number of subjects: 88
Study: 25824556

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (MgSO4) 5 g in normal saline infused over 6 hours, administered 2 days before surgery, repeated the day before and during surgery.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (control group).
Number of subjects: 60
Study: 23660312

Group type: EXPERIMENTAL
Intervention: Wide posterior release (Group A, n = 15)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Posterior soft tissue release alone (Group B, n = 22)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Wide posterior release (Group A, subgroup A1)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Posterior soft tissue release alone (Group B, subgroup B1)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Wide posterior release (Group A, subgroup A2)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Posterior soft tissue release alone (Group B, subgroup B2)
Number of subjects: 37